News

June 6, 2018June 6, 2018

Foundation Medicine and Merck Collaborating to Develop Diagnostic Tests for Keytruda

News

Foundation Medicine will develop companion diagnostic tests for use with Keytruda (pembrolizumab) in collaboration with Merck (known as MSD outside the U.S. and Canada), Keytruda’s maker. “By collaborating, Merck and Foundation Medicine can continue ... Read more

June 5, 2018June 5, 2018

Imfinzi Improves Survival of Patients with Advanced Non-small Cell Lung Cancer, Phase 3 Trial Shows

News

Interim analysis of a Phase 3 trial shows that treatment with Imfinzi (durvalumab) extends the survival of patients with advanced, inoperable non-small cell lung cancer (NSCLC), according to AstraZeneca and ... Read more

June 1, 2018

Tecentriq with Avastin and Chemotherapy Prolongs Life of Patients with Metastatic Lung Cancer, Phase 3 Study Shows

News

Adding Tecentriq (atezolizumab) to a combination of Avastin (bevacizumab) and chemotherapy extended the survival of metastatic non-squamous non-small cell lung cancer (NSCLC) patients, an early analysis of Genentech’s Phase 3 trial ... Read more

May 30, 2018May 30, 2018

1st Patient Treated in Phase 1 Trial of FS118, Potential Immunotherapy for Advanced Cancers

News

A Phase 1 trial testing FS118 – F-star‘s antibody designed to target two immune checkpoint proteins – in solid and advanced cancers has dosed a first patient, the company announced. The ... Read more

May 29, 2018May 29, 2018

First Lung Cancer Patient Treated with NEO-PV-01 Vaccine in Phase 1 Trial

News

Neon Therapeutics has dosed the first lung cancer patient with its investigational vaccine NEO-PV-01, in combination with the checkpoint inhibitor Keytruda (pembrolizumab) and chemotherapy, in a Phase 1b clinical trial. Specifically, ... Read more

May 25, 2018May 25, 2018

Quizartinib Prolongs Survival in Some Patients with Relapsed or Refractory AML, Phase 3 Study Shows

News

Quizartinib, an inhibitor of the FLT3 molecule, significantly prolongs overall survival compared to salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) carrying FLT3-ITD mutations, and who ... Read more

May 23, 2018May 23, 2018

Tecentriq-Cotellic Combo Fails to Lengthen Survival in Advanced Colorectal Cancer

News

A combination treatment of Tecentriq (atezolizumab) and Cotellic (cobimetinib) did not extend survival of patients with advanced or difficult-to-treat colorectal cancer (CRC) compared to standard therapy, Roche’s Phase 3 clinical ... Read more

May 22, 2018

Phase 1 Trial on Treos’ Potential Colorectal Cancer Vaccine Doses First Patient

News

A Phase 1 trial evaluating the investigational colorectal cancer vaccine PolyPEPI 1018 in patients whose disease has metastasized has begun dosing participants, Treos Bio announced. The trial (NCT03391232), which is still recruiting, is ... Read more

May 18, 2018

Eli Lilly Acquires Pegilodecakin, Potential Immunotherapy Now in Phase 3 Trial

News

Eli Lilly announced that it is acquiring ARMO BioSciences and its lead treatment candidate pegilodecakin (AM0010), an investigational immunotherapy that has shown clinical benefit in multiple types of cancer and is now in a pivotal ... Read more

May 16, 2018May 16, 2018

Humanized CAR T-cell Therapy Seen to Treat Metastatic Colorectal Cancer in Mouse Study

News

A humanized chimeric antigen receptor (CAR) T-cell immunotherapy was seen successfully kill tumor cells and prevent further spread of colorectal metastatic cancer in mouse models of the disease. The treatment, which ... Read more